ETD system

Electronic theses and dissertations repository

 

Tesi etd-07202009-150645


Thesis type
Tesi di dottorato di ricerca
Author
DELLA PINA, MARIA CLOTILDE
URN
etd-07202009-150645
Title
Doxorubicin Eluting Bead-Enhanced Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Clinical Study
Settore scientifico disciplinare
MED/36
Corso di studi
TECNOLOGIE PER LA SALUTE: VALUTAZIONE E GESTIONE DELLE INNOVAZIONI NEL SETTORE BIOMEDICALE
Commissione
tutor Prof. Lencioni, Riccardo
Parole chiave
  • HCC
  • Chemoembolization
  • RF ablation
Data inizio appello
29/09/2009;
Consultabilità
parziale
Data di rilascio
29/09/2049
Riassunto analitico
Background: Experimental studies have shown synergy between radiofrequency (RF) ablation and adjuvant chemotherapy in animal tumour models. We aimed to assess safety and efficacy of doxorubicin-eluding bead (DEB)-enhanced RF ablation in the treatment of human hepatocellular carcinoma (HCC).<br>Methods: Twenty patients with single HCC ranging 3.3-7.0 cm (mean, 5.0 cm ±1.4) showing evidence of residual viable tumor after standard RF ablation underwent intra-arterial DEB administration (50-125 mg doxorubicin; mean, 60.2 mg ±21.8). Follow-up period ranged 6-20 months (mean, 12 months ±5).<br>Results: No major complication occurred. No deterioration of liver function was observed. The volume of treatment-induced necrosis – as measured on imaging – increased from 48.1 cm3 ±35.7 after RF ablation to 75.5 cm3 ±52.4 after DEB administration, with an increase of 60.9% ±39.0. The enhanced effect resulted in confirmed complete response (CR) of the target lesion in 12 (60%) of 20 patients. Incomplete response with persistence of &lt;10% of initial tumor volume was observed in 6 (30%) of 20 patients, and local tumor progression in 2 (10%) of 20. <br>Conclusions: Intra-arterial DEB administration substantially increases the effect of RF ablation. DEB-enhanced RF ablation is safe and results in a high rate of CR in patients refractory to standard RF treatment. <br> <br>
File